ADC Therapeutics SA Shares Outstanding 2019-2023 | ADCT
ADC Therapeutics SA shares outstanding from 2019 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ADC Therapeutics SA Annual Shares Outstanding
(Millions of Shares) |
| 2022 |
78 |
| 2021 |
77 |
| 2020 |
65 |
| 2019 |
49 |
| 2018 |
47 |
ADC Therapeutics SA Quarterly Shares Outstanding
(Millions of Shares) |
| 2023-03-31 |
81 |
| 2022-12-31 |
78 |
| 2022-09-30 |
78 |
| 2022-06-30 |
77 |
| 2022-03-31 |
77 |
| 2021-12-31 |
77 |
| 2021-09-30 |
77 |
| 2021-06-30 |
77 |
| 2021-03-31 |
77 |
| 2020-12-31 |
65 |
| 2020-09-30 |
71 |
| 2020-06-30 |
63 |
| 2020-03-31 |
51 |
| 2019-12-31 |
|
| 2019-09-30 |
51 |
| 2019-06-30 |
48 |
| 2018-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.191B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
